Identifying leukemia stem cells - Is it feasible and does it matter?

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 10-14

  Lutz, Christoph ^a   Hoang, Van T ^a   Buss, Eike ^a   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aldehyde dehydrogenase; Clonal heterogeneity; Leukemia; Leukemia stem cells (LSC); Niche; Xenotransplantation

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STEM CELL; CELL POPULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; LEUKEMIA STEM CELL; MESENCHYMAL STEM CELL; MOLECULAR BIOLOGY; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL NICHE; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

EID: 84882854248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.014     Document Type: Review

References (57)

1. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
2. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
3. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5:738-743.
4. Wang J.C., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005, 15:494-501.
5. Taussig D.C., Miraki-Moud F., Anjos-Afonso F., Pearce D.J., Allen K., Ridler C., Lillington D., Oakervee H., Cavenagh J., Agrawal S.G., Lister T.A., Gribben J.G., Bonnet D. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112:568-575.
6. Taussig D.C., Vargaftig J., Miraki-Moud F., Griessinger E., Sharrock K., Luke T., Lillington D., Oakervee H., Cavenagh J., Agrawal S.G., Lister T.A., Gribben J.G., Bonnet D. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010, 115:1976-1984.
7. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., Canty A.J., Danska J.S., Bohlander S.K., Buske C., Minden M.D., Golub T.R., Jurisica I., Ebert B.L., Dick J.E. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
8. Sarry J.E., Murphy K., Perry R., Sanchez P.V., Secreto A., Keefer C., Swider C.R., Strzelecki A.C., Cavelier C., Recher C., Mansat-De Mas V., Delabesse E., Danet-Desnoyers G., Carroll M. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J. Clin. Invest. 2011, 121:384-395.
9. Ran D., Schubert M., Pietsch L., Taubert I., Wuchter P., Eckstein V., Bruckner T., Zoeller M., Ho A.D. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp. Hematol. 2009, 37:1423-1434.
10. Schubert M., Herbert N., Taubert I., Ran D., Singh R., Eckstein V., Vitacolonna M., Ho A.D., Zoller M. Differential survival of AML subpopulations in NOD/SCID mice. Exp. Hematol. 2011, 39:250-263. e254.
11. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183:1797-1806.
12. Sarkadi B., Ozvegy-Laczka C., Nemet K., Varadi A. ABCG2 - a transporter for all seasons. FEBS Lett. 2004, 567:116-120.
13. Cai J., Cheng A., Luo Y., Lu C., Mattson M.P., Rao M.S., Furukawa K. Membrane properties of rat embryonic multipotent neural stem cells. J. Neurochem. 2004, 88:212-226.
14. Storms R.W., Trujillo A.P., Springer J.B., Shah L., Colvin O.M., Ludeman S.M., Smith C. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc. Natl. Acad. Sci. USA 1999, 96:9118-9123.
15. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., Andreeff M., Goodell M.A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173.
16. Moshaver B., van Rhenen A., Kelder A., van der Pol M., Terwijn M., Bachas C., Westra A.H., Ossenkoppele G.J., Zweegman S., Schuurhuis G.J. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008, 26:3059-3067.
17. Ran D., Schubert M., Taubert I., Eckstein V., Bellos F., Jauch A., Chen H., Bruckner T., Saffrich R., Wuchter P., Ho A.D. Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Exp. Hematol. 2012, 40:155-165. e151.
18. Pearce D.J., Taussig D., Simpson C., Allen K., Rohatiner A.Z., Lister T.A., Bonnet D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23:752-760.
19. Cheung A.M., Wan T.S., Leung J.C., Chan L.Y., Huang H., Kwong Y.L., Liang R., Leung A.Y. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
20. Gerber J.M., Smith B.D., Ngwang B., Zhang H., Vala M.S., Morsberger L., Galkin S., Collector M.I., Perkins B., Levis M.J., Griffin C.A., Sharkis S.J., Borowitz M.J., Karp J.E., Jones R.J. A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 2012, 119:3571-3577.
21. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997, 89:3104-3112.
22. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., Guthridge M.A., Thomas D., Barry E.F., Boyd A., Gearing D.P., Vairo G., Lopez A.F., Dick J.E., Lock R.B. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
23. van Rhenen A., Moshaver B., Kelder A., Feller N., Nieuwint A.W., Zweegman S., Ossenkoppele G.J., Schuurhuis G.J. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007, 21:1700-1707.
24. van Rhenen A., van Dongen G.A., Kelder A., Rombouts E.J., Feller N., Moshaver B., Stigter-van Walsum M., Zweegman S., Ossenkoppele G.J., Jan Schuurhuis G. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
25. Hosen N., Park C.Y., Tatsumi N., Oji Y., Sugiyama H., Gramatzki M., Krensky A.M., Weissman I.L. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 2007, 104:11008-11013.
26. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., van Rooijen N., Weissman I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
27. Kikushige Y., Shima T., Takayanagi S., Urata S., Miyamoto T., Iwasaki H., Takenaka K., Teshima T., Tanaka T., Inagaki Y., Akashi K. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
28. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
29. Bachas C., Schuurhuis G.J., Assaraf Y.G., Kwidama Z.J., Kelder A., Wouters F., Snel A.N., Kaspers G.J., Cloos J. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012.
30. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., Kempski H., Moorman A.V., Titley I., Swansbury J., Kearney L., Enver T., Greaves M. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
31. Notta F., Mullighan C.G., Wang J.C., Poeppl A., Doulatov S., Phillips L.A., Ma J., Minden M.D., Downing J.R., Dick J.E. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
32. Campbell P.J., Pleasance E.D., Stephens P.J., Dicks E., Rance R., Goodhead I., Follows G.A., Green A.R., Futreal P.A., Stratton M.R. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 2008, 105:13081-13086.
33. Mullighan C.G., Phillips L.A., Su X., Ma J., Miller C.B., Shurtleff S.A., Downing J.R. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
34. Pearce D.J., Taussig D., Zibara K., Smith L.L., Ridler C.M., Preudhomme C., Young B.D., Rohatiner A.Z., Lister T.A., Bonnet D. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006, 107:1166-1173.
35. van Rhenen A., Feller N., Kelder A., Westra A.H., Rombouts E., Zweegman S., van der Pol M.A., Waisfisz Q., Ossenkoppele G.J., Schuurhuis G.J. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 2005, 11:6520-6527.
36. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., Scadden D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
37. Doan P.L., Chute J.P. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 2011.
38. Nagasawa T., Omatsu Y., Sugiyama T. Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells. Trends Immunol. 2011, 32:315-320.
39. Wagner W., Horn P., Bork S., Ho A.D. Aging of hematopoietic stem cells is regulated by the stem cell niche. Exp. Gerontol. 2008, 43:974-980.
40. Wagner W., Wein F., Roderburg C., Saffrich R., Diehlmann A., Eckstein V., Ho A.D. Adhesion of human hematopoietic progenitor cells to mesenchymal stromal cells involves CD44. Cells Tissues Organs 2008, 188:160-169.
41. Wagner W., Wein F., Roderburg C., Saffrich R., Faber A., Krause U., Schubert M., Benes V., Eckstein V., Maul H., Ho A.D. Adhesion of hematopoietic progenitor cells to human mesenchymal stem cells as a model for cell-cell interaction. Exp. Hematol. 2007, 35:314-325.
42. Walenda T., Bork S., Horn P., Wein F., Saffrich R., Diehlmann A., Eckstein V., Ho A.D., Wagner W. Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J. Cell Mol. Med. 2010, 14:337-350.
43. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
44. Spoo A.C., Lubbert M., Wierda W.G., Burger J.A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109:786-791.
45. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
46. Wein F., Pietsch L., Saffrich R., Wuchter P., Walenda T., Bork S., Horn P., Diehlmann A., Eckstein V., Ho A.D., Wagner W. N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res. 2010, 4:129-139.
47. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16:2927-2931.
48. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., Prior J.L., Piwnica-Worms D., Bridger G., Ley T.J., DiPersio J.F. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
49. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., Akiyama T., Kuroda H., Kawano Y., Kobune M., Kato J., Hirayama Y., Sakamaki S., Kohda K., Miyake K., Niitsu Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 2003, 9:1158-1165.
50. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., DiPersio J.F. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
51. Gadhoum Z., Delaunay J., Maquarre E., Durand L., Lancereaux V., Qi J., Robert-Lezenes J., Chomienne C., Smadja-Joffe F. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk. Lymphoma 2004, 45:1501-1510.
52. Harrison D.E., Lerner C.P. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 1991, 78:1237-1240.
53. Lerner C., Harrison D.E. 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp. Hematol. 1990, 18:114-118.
54. Essers M.A., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
55. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., Najima Y., Takagi S., Aoki Y., Wake A., Taniguchi S., Shultz L.D., Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
56. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., Fey M., Schouten H., de Greef G., Ferrant A., Kovacsovics T., Gratwohl A., Daenen S., Huijgens P., Boogaerts M. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N. Engl. J. Med. 2003, 349:743-752.
57. Costello R.T., Mallet F., Gaugler B., Sainty D., Arnoulet C., Gastaut J.A., Olive D. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000, 60:4403-4411.